Search results for "Monoamine oxidase A"

showing 10 items of 13 documents

Structure-Activity Relationship Analysis of 3-Phenylcoumarin-Based Monoamine Oxidase B Inhibitors

2018

Monoamine oxidase B (MAO-B) catalyzes deamination of monoamines such as neurotransmitters dopamine and norepinephrine. Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease. Coumarin with a functionalized 3-phenyl ring system is a promising scaffold for building potent MAO-B inhibitors. Here, a vast set of 3-phenylcoumarin derivatives was designed using virtual combinatorial chemistry or rationally de novo and synthesized using microwave chemistry. The derivatives inhibited the MAO-B at 100 nM−1 μM. The IC50 value of the most potent derivative 1 was 56 nM. A docking-based structure-activi…

0301 basic medicineentsyymitParkinson's diseaseParkinsonin tautita311101 natural scienceslääkesuunnittelumonoamine oxidase B (MAO-B)lcsh:Chemistry03 medical and health scienceschemistry.chemical_compoundstructure-activity relationship (SAR)Dopamine3-phenylcoumarinmedicineStructure–activity relationshipoksidoreduktaasitkumariinitta116ta317inhibiittoritOriginal Researchchemistry.chemical_classificationbiologyvirtual drug designta1182General ChemistryCoumarin3. Good health0104 chemical sciences010404 medicinal & biomolecular chemistryChemistry030104 developmental biologyMonoamine neurotransmitterEnzymeBiochemistrychemistrylcsh:QD1-999Docking (molecular)biology.proteinParkinson’s diseaseMonoamine oxidase BMonoamine oxidase Amedicine.drugFrontiers in Chemistry
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Brunner syndrome associated MAOA dysfunction in human dopaminergic neurons results in NMDAR hyperfunction and increased network activity

2020

AbstractBackgroundMonoamine neurotransmitter abundance affects motor control, emotion, and cognitive function and is regulated by monoamine oxidases. Amongst these, monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites. Loss-of-function mutations in the X-linked MAOA gene cause Brunner syndrome, which is characterized by various forms of impulsivity, maladaptive externalizing behavior, and mild intellectual disability. Impaired MAOA activity in individuals with Brunner syndrome results in bioamine aberration, but it is currently unknown how this affects neuronal function.MethodsWe generated human induced pluripotent s…

Brunner syndromeDopaminergicBiologymedicine.diseaseNorepinephrineMonoamine neurotransmitterDopaminebiology.proteinmedicineGRIN2BSerotoninMonoamine oxidase ANeurosciencemedicine.drug
researchProduct

The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes.

2006

Contains fulltext : 35205.pdf (Publisher’s version ) (Closed access) Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder, starting in early childhood and persisting into adulthood in the majority of cases. Family and twin studies have demonstrated the importance of genetic factors and candidate gene association studies have identified several loci that exert small but significant effects on ADHD. To provide further clarification of reported associations and identify novel associated genes, we examined 1,038 single-nucleotide polymorphisms (SNPs) spanning 51 candidate genes involved in the regulation of neurotransmitter pathways, particularly dopamine, nor…

Candidate geneGenetics and epigenetic pathways of disease [NCMLS 6]MedizinReceptors NicotinicTryptophan HydroxylaseNeuroinformatics [DCN 3]0302 clinical medicinePerception and Action [DCN 1]Determinants in Health and Disease [EBP 1]ChildOncogene ProteinsGenetics0303 health sciencesbiologyDNA POOLING ANALYSISPedigree3. Good healthserotoninPsychiatry and Mental healthConduct disorderChild Preschool/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingMonoamine oxidase AdopaminePsychologyFunctional Neurogenomics [DCN 2]Genetic MarkersAdolescentSynaptosomal-Associated Protein 25Single-nucleotide polymorphismassociation studyPolymorphism Single NucleotideMental health [NCEBP 9]Genetic determinismGenomic disorders and inherited multi-system disorders [IGMD 3]03 medical and health sciencesCellular and Molecular NeuroscienceMONOAMINE-OXIDASE-ACognitive neurosciences [UMCN 3.2]SDG 3 - Good Health and Well-beingmental disordersmedicineHumansAttention deficit hyperactivity disorderADHDGenetic Predisposition to Disease5-HT1B RECEPTOR GENEddc:610Medizinische Fakultät » Universitätsklinikum Essen » LVR-Klinikum Essen » Klinik für Psychiatrie Psychosomatik und Psychotherapie des Kindes- und JugendaltersMonoamine OxidaseMolecular Biology030304 developmental biologyGenetic associationDopamine Plasma Membrane Transport ProteinsSEROTONIN TRANSPORTER GENEDOPAMINE-BETA-HYDROXYLASESiblingsReceptors Dopamine D4candidate genemedicine.diseaseTwin studyPREFERENTIAL TRANSMISSIONHaplotypesCATECHOL-O-METHYLTRANSFERASEAttention Deficit Disorder with HyperactivityCONDUCT DISORDERbiology.proteinnoradrenalineDEFICIT/HYPERACTIVITY DISORDERNO EVIDENCE030217 neurology & neurosurgerylinkage disequilibriumMolecular Psychiatry
researchProduct

Immuno-fluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pi…

1990

Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of MAO-A and MAO-B revealed that only about 10% of the melanin-containing neurons are positive for MAO-A, while they are substantially free of MAO-B.

Frozen section procedurebiologymedicine.diagnostic_testMonoamine oxidaseChemistrySubstantia nigraImmunofluorescenceMolecular biologyStainingnervous systemBiochemistrybiology.proteinmedicineCytochemistrysense organsMonoamine oxidase BMonoamine oxidase A
researchProduct

MAOA-VNTR polymorphism modulates context-dependent dopamine release and aggressive behavior in males

2016

A recent [F-18]FDOPA-PET study reports negative correlations between dopamine synthesis rates and aggressive behavior. Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli. We selected from a genetic prescreening sample, strictly case-matched groups of 2 x 12 healthy male subjects with VNTRs predictive of high (MAOA-High) and low (MAOA-Low) MAOA expression. Subjects underwent pairs of PET sessions (dopamine D-2/3 ligand [F-18]DM…

Male0301 basic medicinemedicine.medical_specialtyGenotypeCognitive NeuroscienceDopamineContext (language use)Polymorphism Single NucleotideDevelopmental psychologyYoung Adult03 medical and health sciences0302 clinical medicineDopaminePolymorphism (computer science)Dopamine receptor D2Internal medicineImage Processing Computer-AssistedmedicineHumansMAOAYoung adultMonoamine OxidasebiologyAggressionDopaminergicBrainDMFPAggression030104 developmental biologyEndocrinologyPETNeurologyPositron-Emission Tomographybiology.proteinmedicine.symptomMonoamine oxidase APsychology030217 neurology & neurosurgerymedicine.drug
researchProduct

Chemical sympathectomy and clorgyline-induced stimulation of rat pineal melatonin synthesis

1989

The response to administration of the specific monoamine oxidase A (MAO-A) blocker clorgyline was investigated in adult male Sprague-Dawley rats which were sympathectomized by injection of the false neurotransmitter 6-hydroxydopamine as newborns. In intact animals which served as controls, the contents of pineal indoles melatonin, serotonin, 5-hydroxytryptophan were augmented, and the content of 5-hydroxyindoleacetic acid decreased 90 min following clorgyline injections when compared to saline receiving rats. Sympathectomized animals exhibited similar responses but these were less pronounced. It is suggested that blocking of the oxidation of both MAO-A substrates, noradrenaline and serotoni…

MaleClorgylineSerotoninmedicine.medical_specialtyMonoamine oxidaseStimulationBiologyPineal Gland5-HydroxytryptophanMelatoninClorgylineInternal medicinemedicineAnimalsClorgilineBiological PsychiatryMelatoninSympathectomy ChemicalRats Inbred StrainsHydroxyindoleacetic AcidRatsPsychiatry and Mental healthEndocrinologyNeurologybiology.proteinAntidepressantNeurology (clinical)SerotoninMonoamine oxidase Amedicine.drugJournal of Neural Transmission
researchProduct

20 ans après: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition

2013

Intellectual disability (ID) is characterized by an extraordinary genetic heterogeneity, with >250 genes that have been implicated in monogenic forms of ID. Because this complexity precluded systematic testing for mutations and because clinical features are often non-specific, for some of these genes only few cases or families have been unambiguously documented. It is the case of the X-linked gene encoding monoamine oxidase A (MAOA), for which only one nonsense mutation has been identified in Brunner syndrome, characterized in a single family by mild non-dysmorphic ID and impulsive, violent and aggressive behaviors. We have performed targeted high-throughput sequencing of 220 genes, includi…

MaleModels MolecularBrunner syndromeNonsense mutationMutation MissenseArticleIntellectual DisabilityGeneticsmedicineMissense mutationHumansGenetic Predisposition to DiseaseAmino Acid SequenceMonoamine OxidaseGenetics (clinical)GeneticsFamily HealthbiologyBase SequenceGenetic heterogeneityPoint mutationHigh-Throughput Nucleotide Sequencingmedicine.diseasePedigreeProtein Structure TertiaryAutism spectrum disorderAttention Deficit and Disruptive Behavior DisordersChild Development Disorders Pervasivebiology.proteinAutismFemaleMonoamine oxidase A
researchProduct

A monoamine oxidase B gene variant and short-term antidepressant treatment response.

2007

Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized do…

OncologyAdultMalemedicine.medical_specialtyMirtazapineSingle-nucleotide polymorphismMirtazapineMianserinPharmacologyDouble-Blind MethodInternal medicinemedicineHumansMonoamine OxidaseBiological PsychiatryAllelesPharmacologyPsychiatric Status Rating ScalesDepressive Disorder MajorbiologyReverse Transcriptase Polymerase Chain ReactionDNAMiddle AgedMianserinParoxetineAntidepressive AgentsIntronsParoxetineData Interpretation Statisticalbiology.proteinAntidepressantFemaleMonoamine oxidase BMonoamine oxidase APsychologyPharmacogeneticsSelective Serotonin Reuptake Inhibitorsmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Association study of affective disorders with genetic polymorphisms of monoamine oxidases

2000

Introduction: Monoamine oxidases (MAO) catalyze the oxidative deamination of monoamines like norepinephrine, serotonin and dopamine. The existing MAOs (A and B) have distinct although partially overlapping biological functions and distributions in the brain. MAO A is mainly expressed in catecholaminergic neurons. Thirty-fold differences in enzyme activity of MAO A can be found in cultured cells from different individuals suggesting a genetic determination of enzyme activity. Indeed, a point mutation in the coding region of the gene which creates a restriction site for Fnu4HI alters the activity. Moreover, the pharmacological inhibition of monoamine oxidase A activity is one of the most effe…

Pharmacologymedicine.medical_specialtybiologybusiness.industrymedicine.diseaseGenotype frequencySubstance abusePsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyNeurologyMood disordersInternal medicineGenetic variationmedicinebiology.proteinPharmacology (medical)Neurology (clinical)Monoamine oxidase BAlleleMonoamine oxidase AbusinessBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct